Navigation Links
Edwards Lifesciences Opens New Singapore Heart Valve Facility

SINGAPORE, May 22 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), the world leader in the science of heart valves, today announced the opening of its new heart valve manufacturing facility in Changi North Crescent, Singapore. The state-of-the-art facility produces Edwards' world-leading Carpentier-Edwards PERIMOUNT tissue heart valve replacements, and also serves as the headquarters for Edwards' Asia-Pacific operations, one of the company's fastest-growing regions.

"Edwards' new Singapore facility was developed to meet the global demands for our technologically advanced tissue heart valve replacement products," said Donald E. Bobo, Jr., Edwards' corporate vice president, heart valve therapy. "The opening coincides with our 50th anniversary of partnering with clinicians to develop life-saving innovations and we look forward to serving more patients around the world through our heart valve operations in the United States, Switzerland, and now, Singapore."

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its market-leading heart valve therapies, and critical care and vascular technologies. In 2008, Edwards celebrates 50 years of partnering with clinicians to develop life-saving innovations. The company's global brands, which are sold in approximately 100 countries, include CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.

SOURCE Edwards Lifesciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008
2. Edwards Lifesciences to Webcast Annual Stockholders Meeting
3. Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance
4. Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations
5. Lambert, Edwards & Associates Named Agency of Record for The West Michigan Science & Technology Initiative
6. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
7. Edwards Lifesciences Announces Organizational Changes
8. Edwards Lifesciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Edwards Lifesciences to Host Earnings Conference Call on February 5, 2008
10. Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve
11. Edwards Lifesciences Completes Acquisition of CardioVations Product Line
Post Your Comments:
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/25/2015)... PUNE, India , November 26, 2015 /PRNewswire/ ... The Global Biobanking Market 2016 - 2020 ... biobanks by maintaining integrity and quality in long-term ... and enabling long-term cost-effectiveness. Automation minimizes manual errors ... improves the technical efficiency. Further, it plays a ...
(Date:11/25/2015)... Studies reveal the differences in species of bacteria ... for more effective treatment for one of the most commonly ... --> --> Gum disease is one ... relatively little was understood about the bacteria associated with it ... researchers from the WALTHAM Centre for Pet Nutrition together with ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/10/2015)... , Nov. 10, 2015 ... biometrics that helps to identify and verify the ... is considered as the secure and accurate method ... of a particular individual because each individual,s signature ... results especially when dynamic signature of an individual ...
(Date:10/29/2015)... Minn. , Oct. 29, 2015   MedNet ... supports the entire spectrum of clinical research, is pleased ... Minnesota High Tech Association (MHTA) as one of only ... in the "Software – Small and Growing" category. The Tekne ... individuals who have shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):